Abstract
Thromboembolic diseases are major cause of global mortality. Thrombosis genesis can be induced by endothelial injury, hyperviscosity and fibrinolysis decrease. The anatomic origin of thrombosis disorders differs according to diverse types of pathophysiology.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Agnelli G, Cosmi B, DI Filippo. A randomised, double blind-placebo controlled trial of dermatan sulfate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost 67, 203–208, 1992.
Ashida S, Abiko Y. Inhibition of platelet aggregation by a new agent, ticlopidine. Thromb Heamost 40, 542–550, 1979.
Beaumont JL, Caen JP, Bernard J. Action hémorragique de l’acide acétylsalicylique au cours des maladies du sang. Bull Soc Méd Hôp Paris 71, 1087, 1985.
Bonne C, Martin B, Regnault F. Potentiation of antiaggregating prostaglandins by ticlopidine. Thromb Haemost 46, Abst 67, 1981.
Bourdon P, Jablonski JA, Chao BH, Maraganore JM. Structure—function relation-ships of hirulog peptide interactions with thrombin. FEBS Lett 294, 163–166, 1991.
Bruno J, Yang D, Taylor LA, Leamster G. Role of platelet cAMP and prostaglandin synthesis in platelet aggregation inhibition by ticlopidine hydrochloride. Thromb Heamost 46, Abst 194, 66, 1981.
Cade JF, Buchanan MR, Boneu B, Okleford P. A comparison of the antithrombotic and heamorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation. Thromb Res 35, 613–625, 1984.
Chang JY. The functionnal domain of hirudin a thrombin-specific inhibitor. FEBS Lett 25, 4622–4628, 1986.
Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironnement of the platelet GPIIb/IIIa complex. J Clin Invest 76, 101, 1985.
Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/lIIa receptor in an experimental animal model. Blood 68, 783–786, 1986.
Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelet produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 72, 325, 1983.
Czapek EE, Kwaan HC, Szczecinski M. The effect of sulfated polysaccharide on ATIII. J Lab Clin Med 95, 783–790, 1980.
Ellis DJ, Roe RL, Bruno JJ, Crauston BJ, McSpadden MM. The effect of ticlopidine hydrochloride on bleeding time and platelet function in man. (ABST). Thromb Heamost 46, 1973, 1981.
Harker LA, Slichter SJ. Studies of platelets and fibrinogen kinetics in patients with prosthetic valves. N Engl J Med 283, 1302–1305, 1970.
Harvey RP, Degryse E, Stefani L, Schamber F, Cazenave JP, Courtney M, Tolstoshev P, LECOCQ JP. Cloning and expression of cDNA coding for the anticoagulant hirudin from the bloodsucking leech. Proc Natl Acad Sei USA 83, 1084–1088, 1986.
Haycraft JB. On the action of a secretion abtained from the medicinal leech on the coagulation of the blood. Proc R Soc Lond 36, 478–487, 1884.
Hemker HC, Frank HLL. The mechanism of action of oral anticoagulants and its consequences for the practice of oral anticoagulation. Heamostasis 15, 203–270, 1985.
Jakubowski JA, Maraganore JM. Inhibition of coagulation and thrombin-induced platelets activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin. Blood 75, 399–406, 1990.
Klöcking HP, Markwardt F. Pentosan polysulfate-induced release of plasminogen activator. Heamostasis 6, 370–374, 1977.
Lecompte TH, Kher A, Gaillard JL, Samama M. Pharmacologie des agents antiplaquettairesJ des Mal Vascu]aires 8, 3, 1983.
Lee H, Paton RC, Ruan C, Caen JP. The in vitro effect of ticlopidine on fibrinogen and factor VIII binding to human platelets. Thromb Heamost 46, 590–592, 1981.
Lindahl U. Biosynthesis of heparin and heparan sulfate. Upsal. J Med Sei 82, 78–79, 1977.
Mao SJT, Yates MT, Owen TJ, Krstenansky JL. Interaction of hirudin with thrombin: Identification of a minimal binding domain that inhibits clotting activity. Biochemistry 27, 8170–8173, 1988.
Maraganore JM, Bourdon P, Jablonski JA. Design and characterisation of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29, 7095–7101, 1990.
Maraganore JM, Chao BH, Joseph ML, et al. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem 264, 8692–8698, 1989.
Mardiguian J. Methods of preparation of low molecular weight heparins. Low Molecular Weight Heparins in Clinical Practice. Marcel Dekker Edit New-York, 7–12, 1992.
Markwardt F. Hirudin as an inhibitor of thrombin. Methods Enzymol 19, 924–932, 1970.
Breckenbridge AM. Oral anticoagulant drugs. Sem Heamatol 15, 19–26, 1978.
Doutremepuich C, Lalanne MC, Doutremepuich F, Puyal C. Low molecular weight heparins today: Pharmacological considerations. In: Low Molecular Weight Heparins in Clinical Practice (C. Doutremepuich (Eds)). Marcel Dekker, New-York, pp 85–96 1992.
Johnson M, Heywood JB. Possible mode of action of ticlopidine: A novel inhibitor of platelet aggregation. Thromb Heamost 42, 367, 1979.
Nath N, Niewiarowski S, Joist JH. Platelet factor 4—antiheparin protein releasable from platelets: Purification and properties. J Lab Clin Med 82, 754–768, 1973.
Topol EJ, Scarpace DG, Palabrica TM, Sutor RJ, Fox IH, Maraganore JM. Hirulog, a direct thrombin inhibitor peptide, instead of heparin for routine coronary angioplasty: pilot experience. Circulation (Supplement II), 84, Abstract 2354, 1991.
Rajah SM, Crow MJ, Ahmad R, Watson DA. The effect of dipyridamole on platelet function. Correlation with blood levels in man. Br J Clin Pharmacol 4, 129–133, 1977.
Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombinheparin cofactor. J Biol Chem 248, 6490–6505, 1973.
Scully MF, Kakkar W. Identification of heparin cofactor II as the principal plasma cofactor for the antithrombin activity of pentosan polysulfate (SP54). Thromb Res 36, 187–194, 1984.
Sie P, Ofosu F, Fernandez F, Buchanau MR, Petitou M, Bonneu B. Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides. Br J Haematol 64, J 707–714, 1986.
Soria C, Soria J, Ryckewaert JJ, Holmer E, Caen JP. Anticoagulant activities of pentosane polysulfate: comparison with standard heparin and a fraction of low molecular weight heparin. Thromb Res 19, 455–463, 1980.
Talbot MD, Ambler J, Butler KD, Findlay VS, Peters RF, Tweed MF, Wallis RB. Recombinant desulfato-hirudin (CGP39393) anticoagulant and antithrombotic properties in vivo. Thromb Haemost 61, 77–80, 1989.
Thomas DP, Marton RE, Barrowcliffe TW, Mulloy B, Johnson EA. Antifactor Xa activity of heparan sulfate., 14, 501–506, 1979.
Tollefsen DM, Petska CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 258, 6713, 1983.
Vairel EG. Heparins and fibrinolysis.In: Low Molecular Weight Heparins in Clinical Practice (C. Doutremepuich (Eds)). Marcel Dekker, New-York, pp 51–61, 1992.
Vairel EG, Brouty-Boye H, Toulemonde F, Doutremepuich C. Role de l’activité fibrinolytique indirecte des heparines et de composes voisins dans la prophylaxie des thromboses. Ann Pharma Franç 41, 339–353, 1983.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag New York, Inc.
About this chapter
Cite this chapter
Oualane, F.A., Doutremepuich, F. (1994). Antithrombotic drugs. In: Doutremepuich, C. (eds) Anticoagulation. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-2668-0_2
Download citation
DOI: https://doi.org/10.1007/978-1-4612-2668-0_2
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-7627-2
Online ISBN: 978-1-4612-2668-0
eBook Packages: Springer Book Archive